Is the Val158Met polymorphism of the catechol-O-methyltransferase gene associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate?
The Val158Met polymorphism of COMT is associated with the PSA-progression-free rate of EMP-treated patients in prostate cancer.
Cryoballoon PV isolation significantly modulates the ICANS, but only temporarily for up to 3 months, measured by HRV changes after ablation.